U.S. flag

An official website of the United States government

NM_003001.5(SDHC):c.166A>C (p.Ile56Leu) AND multiple conditions

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Oct 3, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000641919.11

Allele description

NM_003001.5(SDHC):c.166A>C (p.Ile56Leu)

Gene:
SDHC:succinate dehydrogenase complex subunit C [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1q23.3
Genomic location:
Preferred name:
NM_003001.5(SDHC):c.166A>C (p.Ile56Leu)
HGVS:
  • NC_000001.11:g.161328484A>C
  • NG_012767.1:g.19109A>C
  • NM_001035511.3:c.166A>C
  • NM_001035512.3:c.77+4814A>C
  • NM_001035513.3:c.21-12110A>C
  • NM_001278172.3:c.77+4814A>C
  • NM_001407115.1:c.166A>C
  • NM_001407116.1:c.109A>C
  • NM_001407117.1:c.109A>C
  • NM_001407118.1:c.77+4814A>C
  • NM_001407119.1:c.55A>C
  • NM_001407120.1:c.55A>C
  • NM_001407121.1:c.109A>C
  • NM_003001.5:c.166A>CMANE SELECT
  • NP_001030588.1:p.Ile56Leu
  • NP_001394044.1:p.Ile56Leu
  • NP_001394045.1:p.Ile37Leu
  • NP_001394046.1:p.Ile37Leu
  • NP_001394048.1:p.Ile19Leu
  • NP_001394049.1:p.Ile19Leu
  • NP_001394050.1:p.Ile37Leu
  • NP_002992.1:p.Ile56Leu
  • NP_002992.1:p.Ile56Leu
  • LRG_317t1:c.166A>C
  • LRG_317:g.19109A>C
  • LRG_317p1:p.Ile56Leu
  • NC_000001.10:g.161298274A>C
  • NM_003001.3:c.166A>C
  • NR_103459.3:n.191A>C
Protein change:
I19L
Links:
dbSNP: rs1363555121
NCBI 1000 Genomes Browser:
rs1363555121
Molecular consequence:
  • NM_001035512.3:c.77+4814A>C - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001035513.3:c.21-12110A>C - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001278172.3:c.77+4814A>C - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001407118.1:c.77+4814A>C - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001035511.3:c.166A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001407115.1:c.166A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001407116.1:c.109A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001407117.1:c.109A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001407119.1:c.55A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001407120.1:c.55A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001407121.1:c.109A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_003001.5:c.166A>C - missense variant - [Sequence Ontology: SO:0001583]
  • NR_103459.3:n.191A>C - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Gastrointestinal stromal tumor
Synonyms:
Gastrointestinal Stromal Sarcoma; Gastrointestinal stromal tumor, somatic; Gastrointestinal stroma tumor
Identifiers:
MONDO: MONDO:0011719; MeSH: D046152; MedGen: C0238198; Orphanet: 44890; OMIM: 606764; Human Phenotype Ontology: HP:0100723
Name:
Paragangliomas 3 (PPGL3)
Synonyms:
Glomus tumors, familial, 3; SDHC-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome (Paragangliomas 3); PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 3
Identifiers:
MONDO: MONDO:0011544; MedGen: C1854336; Orphanet: 29072; OMIM: 605373

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV000763569Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))		Uncertain significance
(Oct 3, 2023) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Invitae, SCV000763569.7

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This sequence change replaces isoleucine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 56 of the SDHC protein (p.Ile56Leu). This variant is present in population databases (no rsID available, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with SDHC-related conditions. ClinVar contains an entry for this variant (Variation ID: 534375). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 16, 2024